Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesPreferred Shares IssuedShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catheter Precision (VTAK) Deferred Taxes (2024 - 2026)

Catheter Precision (VTAK) reported Deferred Taxes of -$174000.0 for Q1 2026, up 75.97% year-over-year from -$98882.3 in Q1 2025, and up 29.55% on a QoQ basis from -$247000.0 in Q4 2025.

Catheter Precision (VTAK) has 3 years of Deferred Taxes data on file, last reported at -$174000.0 in Q1 2026.

  • Quarterly Deferred Taxes rose 75.97% year-over-year to -$174000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.3 million (changed N/A YoY) and the FY2025 annual result came in at -$1.8 million, down 160.43% from the prior year.
  • Deferred Taxes grew to -$174000.0 in Q1 2026 per VTAK's latest filing, from -$247000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $3.0 million in Q4 2024 and bottomed at -$950000.0 in Q2 2025.
  • The 3-year median for Deferred Taxes is -$210500.0 (2025), against an average of $172166.7.
  • The widest annual swing landed in 2025, when Deferred Taxes plunged 108.1%; it then surged 75.97% in 2026.
  • Tracing VTAK's Deferred Taxes over 3 years: stood at $3.0 million in 2024, then sank by 108.1% to -$247000.0 in 2025, then gained by 29.55% to -$174000.0 in 2026.
  • Per Business Quant, the three latest VTAK Deferred Taxes figures stand at -$174000.0 (Q1 2026), -$247000.0 (Q4 2025), and $78000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Deferred Taxes (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn -
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn -33.00 Mn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn -101.00 Mn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn -351.00 Mn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn -9.40 Mn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn -
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn 300,000.00
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn -
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn -16.70 Mn
10 Catheter Precision 2.01 Mn 1.20 Mn 390,000.00 -174,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -174,000.00
Dec 31, 2025 -214,000.00
Sep 30, 2025 78,000.00
Jun 30, 2025 -950,000.00
Mar 31, 2025 -724,000.00
Dec 31, 2024 3.05 Mn